Improved Long-Term Clinical Outcomes and Safety Profile of Sunitinib Dosing Schedule With 4/2 Switched to 2/1 in Patients With Metastatic Renal Cell Carcinoma

Journal of Cancer - Australia
doi 10.7150/jca.25693
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Ivyspring International Publisher

Related search

Efficacy and Safety of Sunitinib Alternate Day Regimen in Patients With Metastatic Renal Cell Carcinoma in Japan: Comparison With Standard 4/2 Schedule

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2018English

Long-Term Response to Sunitinib Therapy for Metastatic Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2013English

A Phase 2 Trial of Sunitinib in Patients With Advanced Non–clear Cell Renal Cell Carcinoma

European Urology
Urology
2012English

Metastatic Clear Cell Renal Cell Carcinoma With a Long-Term Response to Sunitinib: A Distinct Phenotype Independently Associated With Low PD-L1 Expression

Clinical Genitourinary Cancer
OncologyUrology
2019English

Association of Angiopoietin-2 and Ki-67 Expression With Vascular Density and Sunitinib Response in Metastatic Renal Cell Carcinoma

PLoS ONE
Multidisciplinary
2016English

High-Dose Interleukin 2 in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid Features

PLoS ONE
Multidisciplinary
2017English

Disparities in the Treatment of Patients With IL-2 for Metastatic Renal Cell Carcinoma

Urologic Oncology: Seminars and Original Investigations
OncologyUrology
2010English

Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma

Therapeutic Advances in Urology
Urology
2016English

Durability of Responses in Patients With Metastatic Renal Cell Carcinoma Treated With High Dose Interleukin-2 (HD IL-2)

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy